•     By Sherri
    Oslick

    Gavel_2About
    Court
    Report:  Each week we will report briefly on recently filed
    biotech and pharma cases.


    Schering Corp. et al. v. Teva Pharmaceuticals USA, Inc. et
    al.

    2:10-cv-01058; filed March 2, 2010 in the District
    Court of New Jersey

    • Plaintiffs:  Schering Corp.; MSP Singapore
    Co. LLC

    • Defendants:  Teva Pharmaceuticals USA, Inc.; Teva
    Pharmaceutical Industries Ltd.

    Infringement of U.S. Patent Nos. RE37,721 ("Hydroxy-Substituted
    Azetidinone Compounds Useful as Hypocholesterolemic Agents," issued May
    28, 2002) and 5,846,966 ("Combinations of Hydroxy-Aubstituted Azetidinone
    Compounds and HMG CoA Reductase Inhibitors," issued December 8, 1998)
    following a Paragraph IV certification as part of Teva's filing of an ANDA to
    manufacture a generic version of MSP's Vytorin® (ezetimibe and simvastatin,
    used to treat hyperlipidemia).  View the New Jersey complaint
    here.


    AstraZeneca AB et al. v. Sun Pharma Global FZE et al.

    2:10-cv-10825; filed March 1, 2010 in the Eastern
    District of Michigan

    • Plaintiffs:  AstraZeneca AB; Aktiebolaget Hassle;
    AstraZeneca LP; KBI Inc.; KBI-E Inc.

    • Defendants:  Sun Pharma Global FZE; Sun
    Pharmaceutical Industries, Inc.; Sun Pharma Global Inc.; Sun Pharmaceutical
    Industries, Ltd.; Caraco Pharmaceutical Laboratories, Ltd.

    Astrazeneca AB et al. v. Sun Pharma Global FZE et al.
    3:10-cv-01017; filed February 26, 2010 in the District
    Court of New Jersey

    • Plaintiffs:  Astrazeneca AB; Aktiebolaget Hassle; Astrazeneca
    LP; KBI Inc.; KBI-E Inc
    .
    • Defendants:  Sun Pharma Global FZE; Sun
    Pharmaceutical Industries Inc.; Sun Pharma Global Inc.; Sun Pharmaceutical
    Industries Ltd.; Caraco Pharmaceutical Laboratories Ltd
    .

    The complaints in these cases are substantially
    identical.  Infringement of U.S.
    Patent Nos. 5,877,192 ("Method for the Treatment of Gastric Acid-Related
    Diseases and Production of Medication Using (-)-Enantiomer of Omeprazole,"
    issued March 2, 1999) and 6,143,771 ("Compounds," issued November 7,
    2000) following a Paragraph IV certification as part of Sun's filing of an ANDA
    to manufacture a generic version of AstraZeneca's Nexium® I.V. (esomeprazole sodium
    I.V., used for the treatment of gastroesophageal reflux disease in patients
    with a history of erosive esophagitis).  View the Michigan complaint
    here.


    Hollander v. Ortho-McNeil-Janssen Pharmaceuticals, Inc.
    2:10-cv-00836; filed March 1, 2010 in the Eastern
    District of Pennsylvania

    False marking based on Ortho-McNeil's marking of
    its Risperdone [sic] products indicating that these products are covered by
    U.S. Patent No. 4,804,663 ("3-piperidinyl-substituted 1,2-benzisoxazoles
    and 1,2-benzisothiazoles," issued February
    14, 1989
    ), marking of its Nizoral products indicating that these
    products are covered by U.S. Patent No. 4,335,125 ("1-(1,3-Dioxolan-2-ylmethyl)-1H-imidazoles,"
    issued June 15, 1982), marking
    of its Terconazole products indicating that these products are covered by U.S.
    Patent No. D279,504 ("Vaginal Applicator," issued July 2, 1985), marking of its Ofloxacin
    products indicating that these products are covered by U.S. Patent No. 4,382,892
    ("Benzoxazine derivatives," issued May 10, 1983), and marking of its Razadyne products indicating that
    these products are covered by U.S. Patent No. 4,663,318 ("Method of Treating
    Alzheimer's Disease," issued May
    5, 1987
    ), all of which are expired.  View the complaint
    here.


    Boehringer Ingelheim Pharma GmbH & Co. KG et al. v. Kappos
    1:10-cv-00318; filed February 26, 2010 in the
    District Court of the District of Columbia

    • Plaintiffs:  Boehringer Ingelheim Pharma GmbH &
    Co. KG; Boehringer Ingelheim International GmbH; Boehringer Ingelheim
    Pharmaceuticals, Inc.
    • Defendant:  David Kappos

    Review and correction of the patent term adjustment
    calculation made by the U.S. Patent and Trademark Office for U.S. Patent No.
    7,582,770 ("Viral Polymerase Inhibitors," issued September 1, 2009).  View the complaint
    here.

  •     By James DeGiulio —

    Athersys On
    February 9th, Athersys, Inc. was issued U.S. Patent No. 7,659,118 covering

    multipotent adult stem cells (MASC), their isolation and expansion, and related
    pharmaceutical compositions
    .  In a February 10, 2010 press release, the Cleveland-based company also announced the grant of European
    patent EP 1 218 489 B1, the counterpart to the
    '118 patent.  Athersys adds these patents to an already
    robust patent portfolio covering its stem cell technology, which includes fourteen
    patents and more than 120 global patent applications.

    Both
    the '118 and '489 patents cover the company's MultiStem technology, which is an investigational
    stem cell therapy that has demonstrated therapeutic potential to treat a range
    of problems, including heart attack, stroke, bone marrow transplant rejection, and inflammatory bowel disease.
      MultiStem has the ability to produce a range
    of factors and form multiple cell types.  MultiStem promotes tissue repair and
    healing in multiple ways, such as through the production of multiple
    therapeutic factors produced in response to signals of inflammation and tissue
    damage.
      Unlike traditional stem cell therapies
    that aim to replace damaged tissue, MultiStem produces factors that regulate
    the immune system, protect damaged or injured cells, and promote tissue repair
    and healing, giving the therapy a more drug-like effect.
      Thus, the company believes that
    MultiStem represents a unique "off-the-shelf" stem cell product.

    The '118 patent describes the advantages of using cells from the developed
    individual rather than an embryo, specifically overcoming the problem of tissue
    incompatibility.  The claimed MASC
    are negative for many common antigens, including CD44, CD45, and HLA class I
    and II.  The MASC express
    transcription factors Oct3/4, REX-1, and ROX-1, express telomerase, and respond
    to the growth factor LIF.  The patent
    describes the method of MASC isolation from human bone marrow, after which the
    MASC can be maintained in undifferentiated state or differentiated into several
    cell types, depending on desired use.  The MASC are also suited for ex vivo
    genetic alteration prior to introduction or engraftment into a human patient.  The MASC are described as efficient for a number of uses, including cancer
    treatment, tissue damage repair, induction of immune responses to fight
    infection, and cardiovascular therapy.  The patent contains 11 examples, which
    describe the isolation, differentiation, development, characterization, and
    engraftment of the cells.

    Both
    the U.S. and European patents claim the MASCs and pharmaceutical compositions, as well
    as methods for their production.  The '489 patent contains 21 claims, additionally claiming the use
    of the MASC for agent screening applications.  The '118 patent contains 12 claims; representative
    claims include:

    1.  A cell culture comprising isolated expanded human multipotent, non-embryonic,
    non-germ cells that can differentiate into at least one cell type of each of
    the endodermal, ectodermal, and mesodermal embryonic lineages and express
    telomerase, said cells having undergone at least 10-40 cell doublings in culture.

    9.  A pharmaceutical composition comprising a pharmaceutically acceptable carrier
    and isolated expanded human multipotent, non-embryonic, non-germ cells that can
    differentiate into at least one cell type of each of the endodermal,
    ectodermal, and mesodermal embryonic lineages and express telomerase, said
    cells having undergone at least 10-40 cell doublings in culture, said cells
    obtained from the cell culture of claim 1 or 2.

    10.  A method for making a pharmaceutical composition comprising admixing a pharmaceutically
    acceptable carrier and isolated expanded human multipotent, non-embryonic, non-germ
    cells that can differentiate into at least one cell type of each of the
    endodermal, ectodermal, and mesodermal embryonic lineages and express
    telomerase, said cells having undergone at least 10-40 cell doublings in
    culture, said cells obtained from the cell culture of claim 1 or 2.

    Pfizer In a December 2009 press release, Athersys
    announced
    a strategic
    partnership with Pfizer under which the companies will jointly develop
    MultiStem for
    inflammatory
    bowel disease
    , and a partnership with Angiotech to develop
    MultiStem in acute myocardial infarction and other cardiovascular
    indications. 
    Athersys is still seeking
    partners to develop MultiStem for stroke victims as well as leukemia patients
    who have rejected bone marrow treatments.

    Angiotech On
    February 16, 2010, Athersys, Inc. announced that it has completed patient
    enrollment for its phase I clinical trial which will test administration of
    Multistem to individuals following acute myocardial infarction.

    James
    DeGiulio has a doctorate in molecular biology and genetics from
    Northwestern University and
    is a third-year law
    student at the Northwestern University School of Law.  Dr. DeGiulio
    was a member of MBHB's 2009 class of summer associates, and he can be
    contacted at degiulio@mbhb.com.

  •     By
    Sarah Fendrick

    USPTO Seal Last
    month, the U.S. Patent and Trademark Office released the first issue of
    inventorseye.  Inventorseye is a bimonthly publication
    released by the USPTO in an effort to provide the necessary resources for an
    independent inventor.  The
    electronic publication provides information on events, organizations, and
    meetings of interest to the independent inventor community as well as issues
    that pertain to independent and small entity inventors.

    The
    first issue of inventorseye includes information on how to avoid scams relating
    to obtaining protection for an invention, tips on how to get started in the
    patent protection process, and a letter from the USPTO Director, David Kappos, addressing
    patent reform and its effect on the independent inventor.

    Individuals
    interested in receiving inventorseye can subscribe here.

    Inventorseye

  • Calendar

    March
    9, 2010 –
    "Patent
    Infringement
    Claims, Opinions of Counsel and Attorney-Client Privilege: Best
    Practices for Opinion Letters after Seagate
    and Qualcomm
    " (
    Technology
    Transfer
    Tactics & Strafford) –
    1:00
    – 2:30 PM (EST)

    March 17-18, 2010 – 18th
    Forum on Biotech Patenting
    (C5) –
    Munich,
    Germany

    March 18-19, 2010 – 4th
    Summit on Biosimilars and
    Follow-on Biologics
    *** (
    Center for
    Business Intelligence) –
    Washington, DC

    March
    22-23, 2010
    4th
    Annual Patent Law Institute
    (
    Practising
    Law Institute) –
    San Francisco,
    CA

    March 24-25, 2010 – FDA
    Boot Camp
    *** (
    American Conference
    Institute) –
    New York, NY

    March
    30,
    2010 – "The
    Bilski Decision: Expert Strategies to Manage Its Impact on
    University IP
    "
    (Technology
    Transfer Tactics) –
    1:00 – 2:30 PM (EST)

    April
    7, 2010 –
    First
    Annual Board
    Conference
    (
    U.S.
    Patent and Trademark Office
    Board
    of Patent
    Appeals and Interferences) –
    Alexandria,
    VA

    April
    7-10, 2010 –
    25th
    Annual
    Intellectual Property Law Conference
    (
    American
    Bar
    Association Section of Intellectual Property Law) –
    Arlington,
    VA

    April
    11-17, 2010 –
    Advanced
    Patent Courses
    (
    Patent
    Resources
    Group) –
    Bonita
    Springs, FL

    April
    23-24, 2010 –
    12th
    Comprehensive PCT Seminar
    (
    Franklin Pierce Law Center & World Intellectual Property
    Organization) –
    Concord,
    NH

    April 27-28, 2010 – 4th
    Annual Paragraph IV Disputes
    *** (
    American Conference
    Institute) –
    New York, NY

    April
    27-28, 2010 –
    Corporate
    IP Counsel Summit
    (
    World
    Research
    Group) –
    New
    York, NY

    April
    29,
    2010 –
    26th
    Annual Joint Patent Practice Seminar
    (
    Connecticut,
    New
    Jersey, New York, and Philadelphia Intellectual Property Law
    Associations) – New York, NY

    ***Patent Docs is a media partner of this conference or CLE

  • WIPO The
    Franklin Pierce Law Center and the World Intellectual Property Organization
    (WIPO) will be holding the 12th Comprehensive PCT Seminar on April 23-24, 2010
    in Concord, NH.  The two-day
    seminar will provide participants with in-depth knowledge and understanding of
    the PCT, and will address the following topics:


    Introduction to the PCT system;

    Basics of the PCT;

    Filing International applications by U.S. applicants;

    The International Bureau as a Receiving Office — by choice or by circumstance;

    Signature requirements, agents, common representatives and withdrawals;

    Claiming priority and furnishing of priority documents;

    International search and written opinion of the ISA;

    Recent and upcoming changes;

    International publication;

    Filing a Demand for International Preliminary Examination;

    International Preliminary Examination;

    Correcting defects;

    Amending the International application and filing informal comments;

    Entry Into the National Phase;

    U.S. National Phase entry requirements;

    The PCT from a user's perspective; and

    Where to get help.

    Franklin Pierce Law Center A detailed program
    for seminar can be obtained here.

    The registration
    fee for the
    seminar is $100 (students), $400 (Pierce Law
    alumni), or $450 (non-students)
    .  Those interested in registering for the
    seminar can do so here.

  • New York #3 World Research
    Group (WRG) will be holding its Second Annual Corporate IP Counsel Summit on
    April 27-28, 2010 in New York, NY. 
    The conference will focus on the latest developments in monetizing and
    maximizing IP, patent portfolio optimization.

    Among the
    presentations to be offered by WRG faculty are:

    • Keynote Session
    — Dennis Crouch, Patently-O;
    • Enhancing your
    value as in-house counsel by learning to operate in the new world of open
    innovation (panel discussion);
    • Preparing for
    litigation:  Best practices to
    prepare, assert or defend against a patent assertion which leads to litigation;
    • Overcoming
    barriers to patenting "green" intellectual property;
    • Navigating the
    Patent Office for streamlined, less costly filings;
    • Maximizing patent
    life cycles:  Lessons learned from
    the pharma industry;
    • Adjusting IP
    strategies through the transition from start-up to steady-stay;
    • Adjusting to the
    new normal:  Thriving despite
    budgets and billing pressures;
    • Leveraging proactive
    patent infringement mitigation strategies;
    • Negotiating and
    drafting license agreements for patents and trademarks (panel discussion);
    • Effectively
    quantifying and assessing ROI for IP programs;
    • Examining the
    relationship between standard setting and patent licensing;
    • Latest
    developments in remedies for patent infringement;
    • Best practices
    for protecting business method patents threatened by Bilski; and
    • Assessing Federal
    Circuit case law related to patentable subject matter and beyond (panel discussion).

    The agenda for
    WRG's Corporate IP Counsel Summit including descriptions of each sessions and
    list of speakers, can be found here (Day One;
    Day Two).  A complete brochure for this conference
    can be downloaded here.

    World Research Group The registration
    fee for the conference ranges from $1,895 (corporate rate) to $2,195 (consultant
    and law firm rate).  Those
    interested in registering for the conference can do so here,
    by sending an e-mail to info@worldrg.com, by calling 1-800-647-7600 or
    1-781-939-2500, or by faxing 1-781-939-2543.

  • Manager's
    Amendment of S. 515 Would Eliminate Most Suits

        By Kevin E. Noonan

    Over the past few weeks, close to perhaps one
    hundred actions, characterized as "qui
    tam
    " (or whistleblower) lawsuits have been filed against several large
    companies (including 3M, Monster Cable Products, S.C. Johnson &
    Co., Proctor & Gamble Co., and Novartis Pharmaceuticals, Inc.).  These actions are based on alleged
    violation of 35 U.S.C. § 292(b), the "false marking" portion of the
    patent statute that makes it a violation to intentionally mark an item in
    commerce with a patent number that has expired or does not protect the goods:

    (a)  Whoever, without the consent of the patentee, marks upon, or affixes
    to, or uses in advertising in connection with anything made, used, offered for
    sale, or sold by such person within the United States, or imported by the
    person into the United States, the name or any imitation of the name of the
    patentee, the patent number, or the words "patent," "patentee,"
    or the like, with the intent of counterfeiting or imitating the mark of the
    patentee, or of deceiving the public and inducing them to believe that the
    thing was made, offered for sale, sold, or imported into the United States by
    or with the consent of the patentee; or Whoever marks upon, or affixes to, or
    uses in advertising in connection with any unpatented article the word "patent"
    or any word or number importing the same is patented, for the purpose of
    deceiving the public; or Whoever marks upon, or affixes to, or uses in advertising
    in connection with any article the words "patent applied for," "patent
    pending," or any word importing that an application for patent has been
    made, when no application for patent has been made, or if made, is not pending,
    for the purpose of deceiving the public – Shall be fined not more than $500 for
    every such offense.

    (b)  Any person may sue for the penalty, in which
    event one-half shall go to the person suing and the other to the use of the
    United States.

    Federal Circuit Seal These suits have arisen at this time in part
    because of the Forest Group, Inc. v. Bon Tool Co. case, where the Federal Circuit determined that calculation of the statutory penalty
    for false marking (up to $500 per "offense") would be left to the sound discretion
    of the trial court; this overturned the District Court's calculus that each "offense"
    was the decision to false mark, and created the possibility of a windfall for plaintiffs.  For mass-produced and –sold consumer
    items, a fine of $500 for sale of each improperly-marked item would be catastrophic.  The Federal Circuit is set to hear oral
    arguments on April 6 on a similar case, Pequignot
    v. Solo Cup
    , that will address the question of intent to false mark that
    raises liability under the statute.

    While there has been much to criticize in the
    attempts in this and prior Congresses to pass patent "reform"
    legislation, one provision of the Senate bill, S. 515, contained in the
    recently-released Manager's Amendment seems to provide a quick remedy for this
    rash of qui tam lawsuits.  The
    specific language is contained in Section 2, subsection (k):

    (k) FALSE MARKING.—

    (1)
    IN GENERAL.—Subsection (b) of section 292 of title 35, United States Code, is
    amended to read as follows: ''(b) A person who has suffered a competitive
    injury as a result of a violation of this section may file a civil action in a
    district court of the United States for recovery of damages adequate to
    compensate for the injury.''

    (2)
    EFFECTIVE DATE.—The amendment made by this subsection shall apply to all cases,
    without exception, pending on or after the date of the enactment of this Act.

    Perhaps the most important feature of the proposed
    legislation is its retroactivity:  section (k)(2) would, if passed, support a motion to dismiss for almost
    all of the defendants in all of the qui
    tam
    lawsuits now pending.  On
    the other hand, the proposed legislation converts a public right to a private
    one, and raises the possibility that a false-marking patentee could be subject
    to multiple lawsuits by several of its competitors.  And the proposed change eliminates the government's right to
    half of the fine imposed for false marking.

    Senate Seal Passage of this or any other portion of S. 515, is
    uncertain at best, particularly in view of the broadside from the House
    directed at Senator Leahy and his Senate brethren who have agreed on the latest
    "compromise" (see "House Leadership Says It Lacked 'Adequate Input' on Senate Patent Reform Bill"
    ).  However, it is good to see representative government working at its
    best:  a problem arose for important constituents, and their representatives
    promptly responded.  Would that
    this performance was the norm, and more generally the case for all Congress's
    constituents.  But for the
    companies under the threat of qui tam
    litigation, this amendment could not have come at a better time.

    Hat tip to Alan Krantz of McDonnell, Boehnen,
    Hulbert & Berghoff LLP for contributing to this post.

  •     By Suresh Pillai

    MIT Dismissed as Party in RNAi Dispute

    MIT Seal The U.S. District Court for the District
    of Massachusetts has granted the joint motion filed by plaintiff the Max Planck
    Institute
    and defendant the Massachusetts Institute of Technology to dismiss MIT as a party in a patent suit brought by Max Planck.  The
    focus of the lawsuit is various licensing agreements covering RNA
    interference technologies.  The
    central dispute in the lawsuit concerns whether defendants the Whitehead
    Institute for Biomedical Research
    ,
    MIT, and the University of Massachusetts
    improperly claimed aspects of inventions first created by Max Planck
    researchers (see "Court Report," July 5, 2009, and "Biotech/Pharma
    Docket
    ," February 17, 2010).

    The most recent filing in the case provides for the dismissal
    of MIT as a defendant in the case.  In exchange, MIT has agreed to be bound by any judgment entered against
    the other defendants.  Read MIT's motion
    here.


    Novartis Prevails over Pfizer in ReFacto® Suit

    Novartis The U.S. District Court for the District
    of Delaware has ruled that there is no interference-in-fact between the patent claims of two Novartis patents covering
    truncated Factor VIII variants, biomolecules useful in the treatment of
    hemophilia, and the claims of a patent owned by Genetics
    Institute LLC, a Pfizer Inc. unit.  The Genetics Institute
    originally filed suit in May 2008 alleging that the claims of two Novartis
    patents, U.S. Patent Nos. 6,060,447 and
    6,228,620,
    were anticipated by a Genetics Institute patent, U.S. Patent No. 4,868,112.  The District Court, however, ruled that the
    claims of the '447 and '620 patents were not anticipated by the '112
    patent.  Although the Court
    reasoned that all three patents were directed to the same subject matter, the Court concluded that there was a lack of homology regarding the amino acid
    deletion ranges cited between the '112 and '620 patents.  This lack of overlap also prevented the
    claims of the '447 patent from being obvious in light of the '112 patent.

    Read the District Court's opinion here.


    Cordis Awarded Fees and Costs in Surgical Device
    Suit

    Cordis The U.S. District Court for the Southern District
    of Illinois granted defendant Cordis Corp.,
    a subsidiary of Johnson and Johnson, its motion to have the case declared exceptional
    for the purpose of receiving compensation for attorneys' fees and
    expenses.  Plaintiff MarcTec LLC
    originally filed suit in 2007, alleging that Cordis' Cypher blood vessel stent
    infringed U.S. Patent Nos. 7,128,753 and 7,217,290,
    both of which are owned by MarcTec.  Cordis counterclaimed that the patents-in-suit were invalid.  In an earlier ruling, the District Court granted
    summary judgment of noninfringement in favor of Cordis and dismissed the
    counterclaims without prejudice.

    In this most recent ruling, the Court concluded
    that MarcTec, in pursuing the suit after learning that Cordis' inventions did
    not infringe the main claim at issue, established its case by depending
    upon mischaracterization of the Court's claim construction and the use of
    unreliable expert testimony.  Read the District Court's opinion
    here.

  •      By Bradley Crawford

    EPO On February 19, 2010, the European Patent Office Enlarged Board of
    Appeals issued its decision in In re Abbott
    Respiratory,
    G 0002/08 (EPO Enlarged
    Board of Appeal 2010).  
    In this decision, three questions
    were considered by the Enlarged Board, but only the third question will be considered here:

    (3)  Are any special considerations applicable when
    interpreting and applying Articles 53(c) and 54(5) EPC 2000?

    While the exact meaning of this question is not
    immediately evident to U.S. practitioners, the Board was being asked to
    consider the need for Swiss-style claims in light of EPC 2000 coming into force
    on December 13, 2007.

    Before discussing the Board's decision, it may be useful
    to review the two types of "use" claims that existed in Europe before
    the passage of EPC 2000 and up to the issuance of this opinion.  The first and broadest type of use claim is the
    first medical use claim, which may be written as:

    Compound X for use as a
    medicament.

    The second and more narrow type of use claim is the
    Swiss-style claim, which may be written as:

    The use of compound X for the manufacture
    of a medicament for treating of disease Y.

    After considering the changes made by EPC 2000, the
    Board answered the question as follows:

    Where the subject matter of a claim is
    rendered novel only by a new therapeutic use of a medicament, such claim may no
    longer have the format of a so called Swiss-type claim as instituted by
    decision G 5/83.

    Thus, the use of Swiss-style claims is to be
    forbidden in the future.  Elsewhere
    in the opinion, the Board states that applicants must stop using Swiss-style
    claims no later than three months after the opinion is officially published in
    the Journal of the EPO, which has not happened yet.

    The Board also noted that this new rule has "no
    retroactive effect."  Consequently,
    patents that issued with Swiss-style claims will not be impacted.

    If Swiss-style claims cannot be used, then what
    format can be used?  Rather than
    using Swiss-style claims in the future, applicants should use second medical
    use claims, which may be written as:

    Substance X for the treatment of
    disease.

  •     By
    Donald Zuhn

    Senate Seal Last
    Thursday, Senate Judiciary Committee Chairman Patrick Leahy (D-VT) informed
    those watching the Committee's Executive Business Meeting that the Committee
    had reached a "tentative agreement in principle" regarding patent
    reform legislation (see "Chairman
    Leahy Announces "Tentative Agreement in Principle" on Patent Reform
    Bill
    ").  Chairman Leahy noted that the Committee
    would release details regarding the bill "in the coming days" and after
    consultation with House legislators. 
    He also mentioned that he had been meeting with members of the House
    majority and minority leadership to discuss the Senate bill in an effort to
    prevent the legislation from becoming a "partisan issue."

    On
    Friday, House Judiciary Committee Chairman John Conyers, Jr. (D-MI), Committee
    Ranking Minority Member Lamar Smith (R-TX), and Representative (and House Judiciary Committee
    member) Howard Berman (D-CA) responded to Chairman Leahy's announcement by
    issuing a short statement
    of their own.  The statements
    reads:

    We appreciate the Senate's most recent
    efforts to craft its compromise on patent reform legislation, but those efforts
    have thus far proceeded without adequate input from House members.  Now that we know the substance of the
    Senate's draft compromise, House members are in the process of reviewing the
    proposal in order to arrive at a bill a majority of both chambers can
    support.  We look forward to
    negotiations with the Senate in the hope of achieving such a bill.

    House of Representatives Seal Interestingly,
    the statement was released on the Republicans' separate House Committee on the
    Judiciary website
    ,
    despite being issued by two Democrats and one Republican.  Also of interest is Rep. Berman's
    decision to sign onto the statement, particularly in view of the fact that he
    sponsored H.R. 1908,
    the patent reform bill passed by the House in September 2007 (Chairman Conyers
    and Rep. Smith were two of the bill's 23 co-sponsors).  H.R. 1908 contained a number of
    controversial provisions, including a damages provision that would have limited
    available damages (where actual damages are not established) to a reasonable
    royalty depending on the "economic value properly attributable to the
    patent's specific contribution over the prior art," a provision that would
    have authorized the USPTO to require information from applicants including
    search reports and other information relating to patentability searches; and a
    provision that would have given the USPTO substantive rulemaking authority (see 'Patent "Reform' Bill Passes
    House of Representatives
    ").

    In
    view of the response from Chairman Conyers, Rep. Smith, and Rep. Berman, it may take more than the few days Chairman Leahy believed he would need to secure the support of
    House leadership for his new patent reform bill.